Lilly Sees Quick Return on $2.3B Ajax Buy as Blood Cancer Drug Shows Early Efficacy

Why It Matters

The data could shift the myelofibrosis market away from Incyte’s Jakafi, expanding Lilly’s oncology pipeline and driving revenue growth. Early disease‑modifying signals also raise the drug’s value for future indications.

Key Takeaways

• AJI-11095 cut spleen volume 35% in 70% of patients.
• Same 70% saw 50% symptom improvement at 12 weeks.
• 59% achieved ≥20% reduction in driver mutation allele frequency.
• No dose‑limiting toxicities; safety profile described as clean.
• Lilly plans second‑line studies and tests in polycythemia vera.

Pulse Analysis

Myelofibrosis, a rare chronic blood cancer, affects roughly 50,000 patients in the United States and drives significant clinical burden through splenomegaly, anemia, and debilitating constitutional symptoms. For years, the therapeutic landscape has been dominated by Incyte’s ruxolitinib (Jakafi), the first‑in‑class JAK1/2 inhibitor approved in 2011. Eli Lilly’s $2.3 billion acquisition of Ajax Therapeutics in April 2026 gave the company access to AJI‑11095, an oral JAK2‑selective inhibitor designed to more completely shut down the pathogenic signaling cascade. The deal follows Lilly’s recent purchases of CrossBridge Bio and Kelonia Therapeutics, underscoring a broader strategy to broaden its hematology‑oncology portfolio.

The Phase 1 readout presented at the European Hematology Association meeting showed that 70% of patients receiving AJI‑11095 achieved a ≥35% reduction in spleen volume after 12 weeks, matching the primary efficacy benchmark for Jakafi. Equally striking, the same cohort reported a 50% improvement in symptom burden and a 59% rate of ≥20% reduction in driver‑mutation variant allele frequency, suggesting early disease‑modifying activity. Safety signals were favorable, with no dose‑limiting toxicities and only manageable anemia, positioning the agent as a “potentially best‑in‑class” JAK2 inhibitor in the eyes of analysts.

Looking ahead, Lilly is expanding AJI‑11095 into a second‑line myelofibrosis cohort and exploring high‑risk polycythemia vera, a logical extension given the shared JAK2 pathology. If later‑stage trials confirm these early signals, the drug could capture a sizable share of the $3.1 billion Jakafi market, which grew 11% year‑on‑year in 2025. Such a win would not only validate the Ajax purchase but also boost Lilly’s revenue pipeline and strengthen its competitive stance against Incyte and other emerging JAK inhibitors. Investors will be watching the upcoming data for clues on long‑term commercial potential.